Author

Xiaorong Lin

Observed name: Hongde Li

Institution: Shantou Central Hospital

Observed institutions: Zhejiang Cancer Hospital, Shantou Central Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences

ORCID: 0000-0003-4139-3309

Observed ORCIDs: 0000-0003-4139-3309, 0000-0003-1256-2513

OpenAlex ID: A5066240074

Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA Adverse Event Reporting System

2024 · Xiaorong Lin, Yimin Zhang, et al. · Expert Opinion on Drug Safety · 14

TRIM59 suppresses mitochondrial-associated apoptosis to facilitate progression in papillary renal cell carcinoma via the ACAT1-cardiolipin pathway

2025 · Haiyan Weng, Jiaxin Zhong, et al. · Cell Death and Disease · 12

A high-affinity antibody-drug conjugates Actuximab-MMAE for potent and selective targeting of CEACAM5-Positive tumors

2025 · Yuqi Hu, Xin Du, et al. · Cancer Letters · 8

Identification of Key Genes and FUNCTIONAL Pathway in Radioresistance of Non-Small Cell Lung Cancer

2022 · Shouying Li, Jiaxin Feng, et al. · Cancer Management and Research · 4

NFYB–lncRNA axis resets the tumor microenvironment to promote HCC aggressive progression by a positive feedback loop

2026 · Boxuan Zhou, Qiang Tao, et al. · Acta Pharmaceutica Sinica B · 1

Works count: 6

Citation count: 47

H-index: 4

I10-index: 2